Pharmafile Logo
Pharmafocus logo
Advanced Search

United Therapeutics

Showing 3 posts of 3 posts found.

credit_rich_s

United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure

April 9, 2019
Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension

United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …

News
8655563196_1c0f83c447_z

United Therapeutics buys Arena’s hypertension drug ralinepag in deal worth $1.2 billion

November 16, 2018
Medical Communications Arena, PAH, United Therapeutics, deal sales, hypertension

US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a …

News

Nice rejects United Therapeutics’ cancer drug

July 15, 2016
Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma

The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026